Courcoulas, A. P. et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA 331, 654–664 (2024).
Mingrone, G. et al. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386, 964–973 (2015).
Ikramuddin, S. et al. Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. JAMA 319, 266–278 (2018).
Aminian, A. et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 322, 1271–1282 (2019).
Fisher, D. P. et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA 320, 1570–1582 (2018).
O’Brien, R. et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study. Ann. Intern. Med. 169, 300–310 (2018).
Wolff Sagy, Y. et al. Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart Failure. Nat. Med. 30, 2337–2342 (2024).
American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2020. Diabetes Care 43, S111–S134 (2020).
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).
Stenberg, E. & Näslund, E. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. Int. J. Obes. 47, 251–256 (2023).
Thomas, L. E., Li, F. & Pencina, M. J. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA 323, 2417–2418 (2020).
Funk, M. J. et al. Doubly robust estimation of causal effects. Am. J. Epidemiol. 173, 761–767 (2011).
Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11–22 (2015).
Trujillo, J. M., Nuffer, W. & Smith, B. A. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 12, 204201882199732 (2021).
Douros, J. D., Tong, J. & D’Alessio, D. A. The effects of bariatric surgery on islet function, insulin secretion, and glucose control. Endocr. Rev. 40, 1394–1423 (2019).
Batterham, R. L. & Cummings, D. E. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 39, 893–901 (2016).
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P. & Rothberg, M. B. Early‐ and later‐stage persistence with antiobesity medications: a retrospective cohort study. Obesity 32, 486–493 (2024).
Liss, D. T. et al. Treatment modification after initiating second-line medication for type 2 diabetes. Am. J. Manag. Care 29, 661–668 (2023).
Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553–1564 (2022).
Bashir, B. et al. Microvascular complications of obesity and diabetes—role of bariatric surgery. Obes. Rev. 24, e13602 (2023).
Vivante, A. et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch. Intern. Med. 172, 1644–1650 (2012).
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).
Davies, M. et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397, 971–984 (2021).
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).
Gasoyan, H. et al. One-year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Netw. Open 7, e2433326 (2024).
Hernán, M. A., Wang, W. & Leaf, D. E. Target trial emulation: a framework for causal inference from observational data. JAMA 328, 2446–2447 (2022).
Hernán, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758–764 (2016).
Madenci, A. L. et al. Estimating the effect of bariatric surgery on cardiovascular events using observational data? Epidemiology 35, 721–729 (2024).
VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern. Med. 167, 268–274 (2017).
Inker, L. A. et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737–1749 (2021).
Blecker, S. et al. Validation of EHR medication fill data obtained through electronic linkage with pharmacies. J. Manag. Care Spec. Pharm. 27, 1482–1487 (2021).
Milinovich, A. & Kattan, M. W. Extracting and utilizing electronic health data from Epic for research. Ann. Transl. Med. 6, 42 (2018).
von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 61, 344–349 (2008).
Van Buuren, S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat. Methods Med. Res. 16, 219–242 (2007).
Rubin, D. B. Inference and missing data. Biometrika 63, 581–592 (1976).
Austin, P. C. Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes. J. Clin. Epidemiol. 63, 46–55 (2010).
Raebel, M. A., Schmittdiel, J., Karter, A. J., Konieczny, J. L. & Steiner, J. F. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med. Care 51, S11–S21 (2013).
Source link
